Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (Nilopeg): A multicentre, non-randomised, open-label phase 2 study

The Lancet Haematology

Volumn 2, Issue 1, 2015, Pages e37-e46

  Nicolini, Franck E ^a,b,r   Etienne, Gabriel ^c,r   Dubruille, Viviane ^d,r   Roy, Lydia ^e,r   Huguet, Françoise ^f,r   Legros, Laurence ^g,r   Giraudier, Stéphane ^h,r   Coiteux, Valérie ^i,r   Guerci Bresler, Agnès ^j,r   Lenain, Pascal ^k,r   Cony Makhoul, Pascale ^l,r   Gardembas, Martine ^m,r   Hermet, Eric ^n,r   Rousselot, Philippe ^o,r   Amé, Shanti ^p,r   Gagnieu, Marie Claude ^q   Pivot, Christine ^q   Hayette, Sandrine ^a,r   Maguer Satta, Veronique ^b,r   Etienne, Madeleine ^a,r   Dulucq, Stéphanie ^r   Rea, Delphine ^r,s   Mahon, François Xavier ^r   more..

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT BERGONIÉ   (France)

^d HÔTEL DIEU   (France)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f La Croix du Sud Hospital   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j CHU NANCY BRABOIS   (France)

^k CENTRE HENRI BECQUEREL   (France)

^l Centre Hospitalier de la Region d'Annecy   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^o CENTRE HOSPITALIER DE VERSAILLES   (France)

^p HÔPITAL CIVIL   (France)

^q EDOUARD HERRIOT HOSPITAL   (France)

^r HAUT LÉVÊQUE HOSPITAL   (France)

^s SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; NILOTINIB; PEGINTERFERON ALPHA2A; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; MACROGOL DERIVATIVE; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BRAIN HEMATOMA; CHOLESTASIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; CORONARY ARTERY OBSTRUCTION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ELECTROLYTE DISTURBANCE; EVENT FREE SURVIVAL; EYE DISEASE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART DISEASE; HISTOCOMPATIBILITY; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; INFECTION; INSOMNIA; LIVER DISEASE; LYMPHOCYTOPENIA; MALAISE; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OPHTHALMOPLEGIA; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PARALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; QUALITY OF LIFE; RASH; REAL TIME POLYMERASE CHAIN REACTION; SEIZURE; SKIN DISEASE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; THYROID DISEASE; URINARY TRACT DISEASE; VASCULAR DISEASE; VOMITING; XERODERMA; CLINICAL TRIAL; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PYRIMIDINES; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84923068128     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(14)00027-1     Document Type: Article

References (39)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identifi ed by quinacrine fl uorescence and Giemsa staining. Nature 1973; 243: 290-93.
2. O'Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancel Oncol 2000; 1: 207-11.
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
5. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-63.
6. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983; 62: 689-92.
7. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 2001; 98: 3074-81.
8. Nicolini FE, Hayette S, Legros L, et al. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. Leuk Res 2011; 35: 80-86.
9. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511-21.
10. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood 2004; 104: 4245-51.
11. Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228-35.
12. Michallet M, Maloisel F, Delain M, et al. Pegylated recombinant interferon α-2b vs recombinant interferon α-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18: 309-15.
13. Johnson-Ansah H, Guilhot J, Rousselot P, et al. Tolerability and effi cacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia. Cancer 2013; 119: 4284-89.
14. Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome. Haematologica 2008; 93: 770-74.
15. Kantarjian H M, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-51.
16. Kantarjian H M, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123-29.
17. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized defi nitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172-75.
18. Essers MA, Off ner S, Blanco-Bose WE, et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904-08.
19. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-08.
20. Guilhot J, Baccarani M, Clark RE, et al. Defi nitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 2012; 119: 5963-71.
21. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003; 17: 2318-57.
22. Muller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-63.
23. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114: 4933-38.
24. Craddock C, Szydlo RM, Klein JP, et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 2000; 96: 86-90.
25. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-38.
26. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096-102.
27. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353-60.
28. Saglio G, Hochhaus A, Hughes T, et al. ENESTnd Update: Nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood 2013; 122: 92 (abstr).
29. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-35.
30. Rea D, Rousselot P, Guilhot F, et al. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood 2012; 120: 916 (abstr).
31. Ross DM, Branford S, Seymour JF, et al. Safety and effi cacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-22.
32. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-25.
33. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-39.
34. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative eff ects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016-19.
35. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nature Med 2009; 15: 696-700.
36. Bhattacharya S, Zheng H, Tzimas C, Carroll M, Baker DP, Fuchs SY. BCR-ABL signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood 2011; 118: 4179-87.
37. Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-a monotherapy have distinct cytokine and oligoclonal lymphocyte profi le. PLoS One 2011; 6: e23022.
38. Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28: 1429-35.
39. Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415-23.